

Revive Therapeutics

08:35 18 Nov 2020

Revive Therapeutics in research collaboration to develop psilocybin to treat cancer and discover novel uses of undisclosed psychedelic compounds

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) has entered into an exclusive research collaboration agreement with PharmaTher Inc to accelerate the development of psilocybin to treat cancer and the discovery of novel uses of undisclosed psychedelic compounds.

PharmaTher is a wholly-owned subsidiary of Newscope Capital Corporation (CSE:PHRM), a specialty psychedelics pharmaceutical company.

"Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach," said Revive CEO Michael Frank in a statement Wednesday. "We are excited to advance the development of PharmaTher's recent discovery in the potential of psilocybin to treat certain cancers such as liver carcinoma, melanoma, breast neoplasms, kidney neoplasms and acute myeloid leukemia."

READ: Revive Therapeutics commits to 10 sites for Phase 3 coronavirus trial of bucillamine

Frank added: "We are also leveraging PharmaTher's panaceAI discovery AI platform to discover new uses of undisclosed psychedelic compounds to be potentially used with our oral thin film delivery technology and expand our psychedelics drug pipeline."

Fabio Chianelli, CEO of PharmaTher, noted that his company achieved an important milestone in expanding its patent portfolio with the potential of psilocybin to treat certain cancer indications.

"Our research collaboration with Revive validates our business model in discovering novel uses of psychedelics with panaceAI and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics," Chianelli said. "We are happy to accelerate Revive's objective in building a unique psychedelic drug pipeline via the FDA development and approval process."

Revive said the collaboration will give it exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher's panaceAI psychedelic discovery AI (artificial intelligence) platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive's drug delivery technology.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 0.5

Market Cap: \$117.21 m

1 Year Share Price Graph



March 2020 August 2020 February 2021

Share Information

Code: RVV

Listing: CSE

52 week	High	Low
	0.92	0.04

Sector: Pharma & Biotech

Website: www.revivetherapeutics.com

Company Synopsis:

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).